HPV vaccination programmes are more likely to achieve sustained coverage when political commitment is embedded in formal national policy frameworks and supported by sustained public financing, rather than short-term or discretionary initiatives.
Comparative experience from countries progressing towards the elimination of HPV cancers shows that positioning HPV vaccination as a national cancer prevention policy, rather than as a standalone immunisation activity, is associated with stronger ownership and more consistent implementation over time [1, 2].
WHO guidance on cervical cancer elimination positions HPV vaccination as a core intervention to be delivered through national immunisation programmes, rather than as a time-limited or pilot initiative. In the European context, this approach is reinforced by regional cancer policy frameworks, including Europe’s Beating Cancer Plan, which explicitly position HPV vaccination as a cornerstone of cancer prevention and elimination efforts [3]. This underscores the importance of embedding vaccination within durable health policy and planning instruments, including alignment with national cancer control strategies and elimination efforts [4].
Sustained political commitment to vaccination programmes coupled with predictable, sustained public financing integrated within routine national immunisation budgets is critical to programme continuity. Reliance on short-term or ad-hoc funding increases vulnerability to programme interruption. Such commitment is key in the context of interventions requiring long-term delivery such as HPV vaccination [4, 5, 6].
HPV vaccination programmes are more effective when leadership responsibilities, evidence-to-policy-pathways, and cross-sector coordination mechanisms are clearly defined and institutionalised.
Evidence from global guidance and immunisation policy research shows that clear leadership and formal decision-making structures strengthen the translation of scientific evidence into national vaccination policy, reducing delays and ambiguity in implementation [4,5,10,11,12].
National Immunization Technical Advisory Groups (NITAGs), which are established in most countries in the WHO European Region, provide a structured mechanism for evidence-informed decision making [7]. Within Europe, their role is reinforced by regional norms and scientific guidance from the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, contributing to the transparency, credibility and legitimacy of vaccination policy decisions, including those related to new or expanded vaccines [8,9].
Experience from HPV and other adolescent immunisation programmes highlights that effective coordination between health and education sectors is critical where schools are involved in delivery, and that lack of clarity in leadership, roles and cross-sector decision making can delay implementation and reduce policy coherence, even when political commitment and accountability mechanisms exist [10,11,12].
Sustained HPV vaccination programme performance depends on explicit accountability arrangements that link policy commitments to regular performance review and corrective action when implementation falls short.
Global immunisation guidance consistently highlights that political commitment and policy adoption alone are insufficient to sustain high vaccination performance without explicit accountability mechanisms, including defined responsibility for monitoring progress and responding to underperformance [3,7,13]. Within the European context, Europe’s Beating Cancer Plan sets a clear accountability benchmark by committing to at least 90% HPV vaccination coverage in girls and a significant increase in coverage among boys, and ensure that 90% of the EU population who qualifies for cervical cancer screening is offered screening by 2025. [3].
Strategic frameworks such as the Immunization Agenda 2030 emphasis country ownership, governance, and accountability as core conditions for sustained immunisation delivery, calling for regular review of progress and timely corrective action where implementation falls short [7,14].
Experience from HPV vaccination programmes, including within the WHO European Region, demonstrates that clear accountability and coordinated national action are particularly critical during periods of programme disruption or declining public confidence, enabling recovery of coverage through active corrective measures rather than reliance on delivery systems alone [14,15,16]. Together, these experiences underline that accountability for sustained delivery is a governance function, enabling countries to respond to challenges, maintain public trust, and protect long-term programme performance [15,16].
